California Research Agency Targeting Multimillion-Dollar Gene Therapy Costs

Effort is part of new priorities for $3.9 billion in CIRM spending

The California stem cell and gene therapy agency’s drive to maximize the impact of its last $3.9 billion focuses sharply this week on making its potential treatments affordable and accessible, a goal mandated by Golden State voters nearly four years ago.

Also up for consideration on Friday is a proposal to step up its training program and create a new effort to develop hybrid skillsets through cross-disciplinary internships. 

The new, proposed goals of the California Institute for Regenerative Medicine (CIRM) were revealed